Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

• Autori principali: Jin-Woo Park (Autore), Jong-Min Kim (Autore), Ji Hyeon Noh (Autore), Kyoung-Ah Kim (Autore), Hyewon Chung (Autore), EunJi Kim (Autore), Minja Kang (Autore), Ji-Young Park (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2022-03-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Dapagliflozin, a selective sodium-glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...